Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | RPA1 | P27694 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30370342 | 1.00 | MEN1 (0.57) | MEN1KMT2AALDH1A1NPSR1HTT | |
| SCHEMBL3063301 | 0.89 | MEN1 (0.54) | MEN1KMT2AALDH1A1NPSR1HTT | |
| SCHEMBL13078465 | 0.87 | MEN1 (0.56) | MEN1KMT2AALDH1A1NPSR1HTT | |
| SCHEMBL13044122 | 0.84 | MEN1 (0.53) | MEN1KMT2AHTTSMN1; SMN2KDM4E | |
| SCHEMBL4944264 | 0.82 | SLC9A1 (0.71) | — | |
| SCHEMBL12670456 | 0.80 | ALDH1A1 (0.68) | MEN1KMT2AALDH1A1NPSR1SMN1; SMN2 | |
| SCHEMBL4944262 | 0.80 | MEN1 (0.55) | MEN1KMT2AALDH1A1NPSR1HTT | |
| SCHEMBL14472215 | 0.78 | MEN1 (0.51) | MEN1KMT2AALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL6355620 | 0.78 | MEN1 (0.51) | MEN1KMT2AALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL2135901 | 0.77 | MEN1 (0.50) | MEN1KMT2AALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040167204-A1 | Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotien and metalloenzyme targets | FERNANDEZ-POL JOSE A (US) | 2004-08-26 | — | — | US | claimed |
| US-7351843-B2 | Furancarbonylguanidine derivatives, their preparation and pharmaceutical compositions containing them | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-04-01 | — | — | US | disclosed |
| US-20070299131-A1 | Furancarbonylguanidine Derivatives, Their Preparation and Pharmaceutical Compositions Containing Them | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2007-12-27 | — | — | US | disclosed |
| US-7109243-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2006-09-19 | — | — | US | disclosed |
| EP-1697335-A1 | FURANCARBONYLGUANIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005063727-A1 | FURANCARBONYLGUANIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2005-07-14 | — | — | WO | disclosed |
| US-6803379-B2 | TREATMENT OF VIRAL, BACTERIAL, PARASITIC, PROLIFERATIVE DISEASES, NEURODEGENERATIVE DISEASES, INFLAMMATORY DISEASES, HEAVY METAL POISONING AND IMMUNOGICAL DISEASES WITH THIOPHENE-2-CARBOXYLIC ACID, 2-FUROIC ACID OR DERIVATIVES | POL'S LABORATORIOS BIOTECHNOLOGY, S.A. (AR) | 2004-10-12 | — | — | US | disclosed |
| WO-2004084842-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2004-10-07 | — | — | WO | disclosed |
| US-20040198780-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2004-10-07 | — | — | US | disclosed |
| US-20040167204-A1 | Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotien and metalloenzyme targets | FERNANDEZ-POL JOSE A (US) | 2004-08-26 | — | — | US | disclosed |
| US-20030225155-A1 | Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotein and metalloenzyme targets | POL'S LABORATORIOS BIOTECHNOLOGY, S.A. (AR) | 2003-12-04 | — | — | US | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167204-A1 | Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotien and metalloenzyme targets | ZFX, ZFR, SLC30A6 | MEN1 2438/4885KMT2A 3080/4885ALDH1A1 1453/4885 |
| US-20070299131-A1 | Furancarbonylguanidine Derivatives, Their Preparation and Pharmaceutical Compositions Containing Them | SLC9A1, NHERF1, SLC5A1 | MEN1 2726/4885KMT2A 4059/4885ALDH1A1 297/4885 |
| US-20040198780-A1 | Inhibitors of cathepsin S | CTSS, CTSK, CTSE | MEN1 3552/4885KMT2A 3983/4885ALDH1A1 4380/4885 |
| US-20030225155-A1 | Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotein and metalloenzyme targets | ZFX, ZFR, SLC30A6 | MEN1 2720/4885KMT2A 2922/4885ALDH1A1 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.